Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Clinical trial NCT05833919 · UNKNOWN
Trial details
- NCT number
- NCT05833919
- Sponsor
- Consorzio Oncotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-30
- Primary completion
- 2023-07-01
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.